We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.29 | -24.7863247863 | 1.17 | 1.17 | 0.866577 | 183282 | 1.02595835 | CS |
4 | -0.72 | -45 | 1.6 | 1.65 | 0.866577 | 165031 | 1.25549226 | CS |
12 | -0.37 | -29.6 | 1.25 | 1.75 | 0.866577 | 137344 | 1.42461825 | CS |
26 | -0.56 | -38.8888888889 | 1.44 | 1.75 | 0.866577 | 93109 | 1.40467338 | CS |
52 | -0.79 | -47.3053892216 | 1.67 | 4.59 | 0.866577 | 114191 | 2.0437631 | CS |
156 | -7.01 | -88.8466413181 | 7.89 | 8.64 | 0.866577 | 67575 | 3.20840223 | CS |
260 | -7.44 | -89.4230769231 | 8.32 | 29.4 | 0.866577 | 168588 | 9.2589736 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions